Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
|Videos|April 24, 2014
Reimbursement Changes for Compounded Medications
David G. Miller, RPh, executive vice president and CEO of the International Academy of Compounding Pharmacists, discusses changes in insurance reimbursement for compounded medications.
Advertisement
In this video, David G. Miller, RPh, executive vice president and CEO of the International Academy of Compounding Pharmacists (IACP), discusses changes in insurance reimbursement for compounded medications.
This video was recorded at the National Community Pharmacists Association 115th Annual Convention in Orlando.
Advertisement
Related to this article
Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
Orforglipron Lowers Systolic BP in ATTAIN-1, ATTAIN-2 Analyses
3
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
4
GLP-1 Receptor Agonists and Cancer: Considerations for Specialty Pharmacists
5